# Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

> **NCT01059526** · — · COMPLETED · sponsor: **Shire** · enrollment: 81 (actual)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **DRUG:** ecallantide

## Key facts

- **NCT ID:** NCT01059526
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-01
- **Primary completion:** 2013-09-01
- **Final completion:** 2014-06-01
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2021-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01059526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01059526, "Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01059526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*